Cybin IRL Limited
- Address
- One Spencer Dock, North Wall Quay
Sponsor Overview
Specializations
Major Depressive Disorder
Cybin IRL Limited focuses on clinical research in major depressive disorder, with trials centered on treatment response, symptom improvement, and sustained benefit in adult participants.
- Depression symptom management
- Therapeutic response in MDD
- Durability of antidepressant effect
The company’s research activity in this area reflects a strong interest in psychiatric disorders affecting mood and daily functioning.
Depression and Anxiety Disorders
The sponsor also shows interest in broader depression and anxiety disorders, indicating attention to overlapping mood disorder presentations and related clinical needs.
- Anxiety symptoms
- Mood and affective disorders
- Psychiatric symptom burden
This therapeutic area aligns with research aimed at improving mental health outcomes in populations with persistent affective illness.
Psychiatric Therapeutics
Cybin IRL Limited’s funded studies are concentrated in psychiatric therapeutics, with a particular emphasis on interventions intended for adult patients with depressive illness.
- Adult psychiatric treatment
- Antidepressant therapy
- Clinical outcomes in mental health
Its research portfolio is positioned within the development of new options for central nervous system disorders.
Novel Psychotropic Compounds
The sponsor is involved in research on novel psychotropic compounds, including work related to pharmacodynamics, pharmacokinetics, and safety in human subjects.
- Human safety studies
- Drug disposition and exposure
- Mechanisms of psychiatric activity
This area supports the clinical evaluation of emerging agents for mental health indications.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Investigation of Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneous Deuterated DMT (CYB004) in Depression and Anxiety Disorders |  The Netherlands | Not Recruiting |
| Long-Term Extension Study Evaluating Safety and Efficacy of Deupsilocin Besilate (CYB003) in Major Depressive Disorder Patients |  Czechia Germany Greece Ireland Poland | Recruiting |
| Phase III Double-Blind Randomized Controlled Trial Evaluating Efficacy and Safety of Deupsilocin Besilate (CYB003) in Adults with Major Depressive Disorder | Czechia Germany Greece Ireland Poland | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 20 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders3 trials150 other sponsors
Partnered Research Centres
20 centres- Address
- Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
- Address
- Luisenring J 5, 68159 Mannheim
- Address
- Zernikedreef 8, 2333 CL Leiden
- Address
- Ul. Na Zaspe 3, 80-546 Gdansk
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Vassilissas Sofias Avenue 74, 115 28 Athens
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Cybin IRL Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.